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COST-EFFECTIVENESS OF EDOXABAN, APIXABAN, RIVAROXABAN AND
DABIGATRAN VERSUS WARFARIN FOR STROKE PREVENTION IN
NONVALVULAR ATRIAL FIBRILLATION
M Marchetti1,*, N L Liberato2, C Rognoni3, S Quaglini3
1Hematology Unit, Ospedale Cardinal Massaia, Asti, 2Medicine Unit, Az
Ospedaliera Pavia, Casorate Primo, 3Department of Electrical, Computer and
Biomedical Engineering, University of Pavia, Pavia, Italy
Background: Non-valvular atrial fibrillation (NVAF) causes one fifth of overall
ischemic strokes, therefore, oral anticoagulation with warfarin is recommended
since it can prevent about one third of the events. Novel oral anticoagulants
(NAO), i.e. oral inhibitors of thrombin or factor Xa, compete with warfarin in this
setting since a simplified monitoring is required and intracranial beedings are
significantly reduced.
Aims: We aimed at assessing the cost-effectiveness of NAOs (dabigatran,
apixaban, rivaroxaban, edoxaban), versus warfarin, for stroke prevention in
NVAF patients with CHADS2 score ≥2.
Methods: We built a Markov decision model including 11 health-states.
Quarterly transition probabilities among states were estimated based on data
from published randomized trials. Quality of life estimations for each event or
health-state were derived from reference studies. For each therapeutic strategy,
the model estimated expected quality-adjusted life-years (QALY) in the lifetime
horizon. The economic analysis was performed in the perspective of the Italian
National Health System. Quarterly drug cost of NAOs was €198 versus €3.9 of
warfarin. Future life years and costs were discounted by 3.5% per year,
according to international guidelines. Incremental cost per QALY gained (ICUR)
as compared with warfarin was calculated for each NAO. First- and second-
order (probabilistic) sensitivity analyses were run. The model was developed
and run by TreeAge SW.
Results: NAOs increased quality-adjusted life expectancy by 0.405-0.753
discounted years, as compared with warfarin. Incremental lifetime health-care
costs of patients assigned to NAOS ranged from €3,439 to €4,923. The cost-
effectiveness of NAOs versus warfarin ranged from €4,567/QALY (80%CI:
2,129-8,993) for apixaban to €12,156/QALY (80%CI: 5,147-33,200) for
rivaroxaban. Dabigatran and edoxaban reported intermediate ICUR values:
€6,307/QALY (80%CI: 3,034-13,421) and € €7,713/QALY (80%CI: €3,909-
€17,963), respectively. Second-order sentivity analysis showed that the results
were robust: over 90% of the simulations provided an incremental-cost-
effectiveness ratio lower than €50,000/QALY, irrspectively of the NAO being
compared with warfarin. The results were sensitive to the time in warfarin
therapeutic range, the analysed time horizon, and the impact of anticoagulants
onto quality of life. NAO cost variation by 20% induced ICUR variations by
about €3,000/QALY.
Summary and Conclusion: NAOs are cost-effective drugs for stroke
prevention in moderate-high risk patients with NVAF. Lacking head-to-head
studies, the relative cost-effectiveness of one NAO versus another one is
surrounded by a wide undcertainty. Economic sustainability of widespread NAO
adoption in industrialized countries still needs to be assessed, therefore phase
4 studies should investigate clinical and economic outcomes in specific patient
subgroups, i.e. warfarin-treated patients with a high rate of time-in-treatment-
range.
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ECONOMIC VALUE CREATED BY ADDING RITUXIMAB TO
CHEMOTHERAPY IN THE UNITED STATES FROM 1998-2013
C Reyes1,*, M Danese2, M Gleeson2, M Halperin2, S Skettino3, J Mikhael4
1Genentech Inc, South San Francisco CA, 2Outcomes Insights, Westlake
Village CA, 3Genentech, Inc, South San Francisco CA, 4Mayo Clinic, Scottsdale
AZ, United States
Background: Rituximab has become the standard in diffuse large B-cell
lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic
leukemia (CLL). The incremental cost of adding rituximab to existing
chemotherapy and the value of the life years saved have not been estimated
at the population level. 
Aims: Our objective is to estimate the net economic value of rituximab in the
United States for policy decision-makers.
Methods: We constructed a population effectiveness model from 1998-2013.
Age group, gender, and year-specific incidence rates for each cancer were
estimated from the Surveillance, Epidemiology, and End Results (SEER)
program. Incidence rates were multiplied by Census estimates to calculate total
diagnosed patient counts. Utilization, survival and cost inputs were estimated
using SEER Medicare merged data for patients diagnosed 1999-2009 and
followed through 2010, extrapolated through 2013. First-line utilization of
rituximab plus chemotherapy (R+Chemo) and Chemo Alone were calculated as
a proportion of all diagnosed patients to estimate treated patient counts.
Differences in mean survival between R+Chemo and Chemo Alone for each
cancer were estimated using flexible parametric survival models. The
incremental cost of R+Chemo versus Chemo Alone for each cancer was based
on Medicare paid amounts for all Part A and B services using regression,
accounting for censoring. Costs were computed over 72-months to capture
short and long-term effects, and inflated to 2013 US dollars. The value of a life
year saved ($90,941 in 2013 dollars) was based on published literature (Lee,
et al. 2009). Monte Carlo sampling was used to estimate the 95% uncertainty
intervals (UI).
Results: Across all three cancers from 1998 to 2013, there were 280,819
cumulative life years saved (95% UI, 269,136-293,345). The additional total
costs of care for R+Chemo were $33,525, $23,511, and $31,435 in DLBCL, FL,
and CLL, respectively. Across all 3 tumors, the incremental direct medical cost
of R+Chemo compared to Chemo Alone was $7.0 billion (95% UI $5.8-$8.2
billion), and the resulting economic value of the life years saved was $25.5
billion (95% UI $11.7-$69.1 billion).
Summary and Conclusion: For DLBCL, FL and CLL patients treated with
R+Chemo in the US from 1998-2013, 281,000 life years were saved that
created a net economic value of $18.5 billion.
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COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE PLUS
RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH
FOLLICULAR LYMPHOMA. PRELIMINARY RESULTS
E Sabater1, A Rueda2, A Salar3, A López-Guillermo4, I Oyagüez1, JM Collar5,*
1Pharmacoeconomics & Outcomes Research Iberia, Madrid, 2Oncology
Department, Hospital Costa del Sol, Marbella, 3Hematology Department,
Hospital del Mar, 4Hematology Department, Hospital Clinic, Barcelona, 5Medical
Department, Mundipharma Pharmaceuticals, Madrid, Spain
Background: Follicular lymphoma (FL) is the most common type of indolent
non-Hodgkin´s lymphomas (NHL), and despite substantial improvement in
survival, it is usually incurable in most cases. The disease characteriscally
responds well to first-line therapy but typically manifests repeated relapses with
the need of recurrent therapeutic interventions, with disease-free intervals.
Patients with FL in advanced stages and high-tumour burden usually receive
front-line chemoimmunotherapy, rituximab (R) + chemotherapy, during the so
called induction phase, followed by maintenance therapy with R in patients
who achieve at least a partial response after the induction phase, as it is
recommended by several Clinical Guidelines.
Aims: To evaluate the cost-effectiveness of rituximab-bendamustine (R-B)
compared with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone) as first-line treatment for patients with advanced FL in Spain.
Methods: A Markov model was built to simulate a patient cohort with FL during
a time horizon of 25 years (4 weeks-cycle length). Clinical data were adapted
from two phase III randomized trials, one with the FL patients analyzed by the
German Study group indolent Lymphomas (StiL) which compared R-B with R-
CHOP during the induction phase, followed by the data obtained in the PRIMA
trial during the maintenance therapy with R. Four health states were considered:
progression-free survival (including induction and maintenance), first relapse,
second relapse and death. Transition probabilities were obtained from
progression-free survival curves available in the literature. Mortality rates were
obtained from GLOBOCAN registry and from recently published epidemiological
data after the “rituximab era”. The Study Perspective was the Spanish National
Health System (NHS) and only direct healthcare costs were considered.
Resources consumed during patients treatment and follow-up where identified
by panel of Spanish experts in FL. Unitary costs were obtained from the Drug
Catalogue and e-Salud Database. Drug costs were calculated based on ex-
factory prices with mandatory 7.5% rebate. All costs were updated to € 2013.
Utilities for each health state were obtained from the literature. The final efficacy
measure was quality-adjusted life-years (QALYs). Costs and health outcomes
were discounted at a 3% annual discount rate. To check for the robustness of
the results, a probabilistic sensitivity analysis was performed with 10,000 Monte
Carlo simulations.
Results: The initial treatment and administration costs during the induction
phase were higher with R-B (€16,481.63) compared to R-CHOP (€10,793.97).
Nevertheless, at the end of the 25 year period, in the deterministic analysis, and
considering only the GLOBOCAN registry mortality rate, R-B first line strategy
accounted a total cost of €686,848.46 compared to €725,450.80 for R-CHOP.
Health benefits measured as QALYs was higher in R-B with 14.25 QALYs than
in R-CHOP with 13.95 QALYs. In the probabilistic analysis, R-B was a dominant
strategy compared to R-CHOP in 99.9% of the simulations.
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